UNC Lineberger Comprehensive Cancer Center / University of North Carolina

Chapel Hill, North Carolina 27599

1 studies enrolling now · 9 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Diffuse, Large B-Cell, Lymphoma, Disease, Hodgkin, Follicular Lymphoma, Grade 3, Follicular Lymphoma, Grade 3b, HER2 Positive Breast Cancer, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, B-cell

Studies at this site

• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 — Recruiting now
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer — Completed
• Safety Study of SEA-CD40 in Cancer Patients — Stopped early
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) — Completed
• Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma — Stopped early
• Safety Study of SGN-CD70A in Cancer Patients — Completed
• A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma — Completed
• A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma — Stopped early